Role of RUNX2 in Melanoma: A New Player in Tumor Progression and Resistance to Therapy by Pulica, Rachael et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books







Role of RUNX2 in Melanoma: A 
New Player in Tumor Progression 
and Resistance to Therapy
Rachael Pulica, Karine Cohen Solal and Ahmed Lasfar
Abstract
RUNX2, a transcription factor, initially known for its indispensable role in skeletal 
development. RUNX2 is essential for osteoblast differentiation and the maintain of 
the osteocyte balance. RUNX2 acts directly on osteoblasts via Fgf pathway or on mes-
enchymal progenitors through Hedgehog, Wnt, Pthlh and DLX5. Currently, many 
reports point its critical role in the progression and metastasis of several cancer types. 
RUNX2 is involved in EMT process, invasion and metastasis through the modulation 
of important oncogenic pathways, including Wnt, FAK/PTK and AKT. In mela-
noma, RUNX2 is a key player in mediating intrinsic RTK-associated pro-oncogenic 
properties. We have showed a dramatic up regulation of RUNX2 expression with 
concomitant up-regulation of EGFR, IGF-1R and AXL, in melanoma cells rendered 
resistant to BRAF mutant inhibitors. Approximately half of melanomas carry BRAF 
mutations which enhance tumor invasion and metastasis. In this chapter, we describe 
the potential mechanisms, leading to the upregulation of RUNX2 in melanoma with 
BRAF mutations. We also highlight the critical role of PI3K/AKT in the expression 
and activation of RUNX2, and its consequences on the regulation of many critical 
factors, controlling cancer invasion and metastasis.
Keywords: Cancer and metastasis, melanoma, RUNX2, BRAF, PI3K/AKT, Wnt, 
Pthlh and DLX5, EGFR, IGF-1R and AXL
1. Introduction
Runt-related transcription factor 2 (Runx2) belongs to RUNX family, consisting 
of three members, Runx1, Runx2, and Runx3. All members are highly conserved 
with a 128 amino acid DNA binding/protein binding domain runt. In contrast to 
other RUNX members, RUNX2 holds a variable poly-glutamine, poly-alanine repeat 
domain [1]. Natural discrepancy within this repeat could alter the transactivation 
potential of RUNX2 which acts as an evolutionary ‘tuning button’ for the control of 
suggested to skull shape. The role of Runx2 is critical in skeletal development, and its 
alteration or low expression often lead to skeletal dysplasia. Runx2 plays important 
role in the process of mesenchymal stem cells differentiation into osteoblasts, and 
ultimately to osteocyte. Runx2 is required for the proliferation of pre-osteoblasts in 
whole skeletons and mesenchymal cells in sutures. Indeed, Runx2 is required for the 
commitment of mesenchymal cells to osteoblast lineage cells [2]. Thus, Runx2 makes 
a condensed cell layer of uncommitted mesenchymal cells or osteoblast progenitors 
by increasing their proliferation and facilitates their differentiation into osteoblast 
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lineage cells. RUNX2 modulates the balance between osteoblasts and osteocytes, 
by either stimulating or inhibiting the osteoblast differentiation, occurring via the 
modulation of many factors and signaling pathways, including hedgehog signaling 
(Gli1, Ptch1 and Ihh), FGFR signaling (FGFR2 and FGFR3), Wnt signaling (Tcf7 
and Wnt10b), Pth1r, Dlx5, Tnc, and Ncam1 (Figure 1). Defects or alterations in the 
expression or the activity of these factors or signaling pathways, may lead to skeletal 
dysplasia. Therefore, Runx2 could be used as target for the development of novel 
therapeutic strategies for bone-related diseases.
Besides, it is critical role in osteoblast differentiation, RUNX2 is also involved 
in the regulation of chondrocyte proliferation during bone formation. However, 
Runx2 expression in terminal hypertrophic chondrocytes is not essential for vas-
cular invasion into the cartilage, but is for their survival and trans-differentiation 
into osteoblasts. Studies in animal models, showed that the trans-differentiation is 
required for trabecular bone formation in embryonic and neonatal stages, but not 
for procuring normal bone structure and volume in young and elder animals [3].
2. Multifaceted role of RUNX2 in cancer
The role of RUNX2 in cancer promotion has been well described in many cancer 
types. The common feature of those cancers is the elevated level of RUNX2 expres-
sion. Although, numerous similarities have been reported for the pro oncogenic role 
of RUNX2, some differences are also described (Figure 2).
In breast cancer (BC), early studies have shown a correlation between RUNX2 
expression and the “Triple Negative” phenotype [4]. Analysis of tissue microarrays 
shown that high level of RUNX2 expression is associated with the triple-negative 
breast cancer phenotype and a low survival of BC patients, in comparison with 
patients, displaying reduced level of RUNX2 expression. Apparently, in triple 
negative cells, RUNX2 promotes Wnt and TGF-beta signaling [5]. RUNX2 is capable 
Figure 1. 
RUNX2 and skeletal development. RUNX2 promotes osteoblast differentiation via several signaling pathways. 
RUNX2 directly acts on osteoblasts via Fgfr1 and Fgr2 to induce their differentiation and their promotion to 
osteocytes. RUNX2 acts on mesenchymal cells and induces specific pathways to enable osteoblast differentiation.
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to regulate different factors, playing critical role in either inhibiting or stimulating 
Wnt pathway. RUNX2 can interact with SMAD3 to promote TGF-beta signaling, in 
addition, to its direct interaction with the Estrogen receptor-alpha (ER-α), enabling 
the expression of aromatase, an estrogen producing enzyme. Increasing the level of 
estrogens, which in turn stimulate cell proliferation of BC cells [5].
It has been also reported that RUNX2 directly regulates TGFβ-induced levels of 
PTHrP, the level of MMP13 and MMP9, IL-8, bone sialoprotein and OPN [6–11]. 
Furthermore, we and others found that irregularities in RUNX2 expression induce 
EMT changes in some mammary epithelial cell lines and twists normal acini struc-
ture [6, 11, 12], strongly suggesting that RUNX2 plays a critical role in early breast 
cancer progression [6].
More recently, it has been demonstrated that RUNX2 was involved in breast 
cancer bone metastasis. This pro-metastatic role is mediated through integrin 
alpha5 [13].
In hepatocellular carcinoma (HCC), a significant increase of RUNX2 has been 
established in both HCC samples and cell lines. It has been demonstrated that 
RUNX2 promotes HCC cell migration and invasion via MMP9 [14]. In addi-
tion, RUNX2 increases the pro-metastatic process via MiR-23a and Mgat3 direct 
targeting [15].
In prostate cancer, RUNX2 has been also reported as cancer promotor. When 
RUNX2 is overexpressed in a C4-2B prostate cancer cell line, the invasiveness is 
greatly enhanced, and transcription factors involved in EMT (SOX9, SNAI2, and 
SMAD3) are upregulated [6, 16]. RUNX2 siRNA treatment of the prostate and 
breast cancer cells decreased migration and invasion of the cancerous cells [6, 17].
Figure 2. 
RUNX2 and promotion of cancer. RUNX2 promotes cancer development of several cancer types: Melanoma, 
hepatocellular carcinoma, prostate cancer, colon cancer, thyroid cancer, gastric cancer, osteosarcoma and breast 
cancer. To promote cancer progression, RUNX2 induces several pathways, relevant to each cancer type.
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In gastric cancer (GC), a correlation between RUNX2 expression and invasion/
metastasis has been established. Patients with GC tumors displaying low RUNX2 
expression had a better outcome than those with high RUNX2 expression [18, 19]. 
RUNX2 was identified as an independent prognostic indicator for GC patients 
with a COX regression analysis. In an orthopedic GC nude mouse model, RUNX2 
significantly increased the invasion and metastatic potential of the GC cells. In vitro 
studies reflected a significant increase in migration and invasion abilities of GC cells 
connected to an increase in RUNX2.
RUNX2 promotes metastasis and invasiveness of GC cells, via the chemokine 
receptor CXCR4 [18]. RUNX2 directly binds to the promotor region of CXCR4, 
enhancing its transcription and leading to overexpression in human GC cells. 
Knockdown of RUNX2 in GC cell lines results in a significant downregulation 
of CXCR4 mRNA. Additionally, CXCR4 is found to have a role in early-stage GC 
development by recruiting stromal cells and establishing a progenitor niche that 
favors tumor growth and development. However, it has been recently demon-
strated that RUNX2 can negatively regulate the expression of Febronectin1 (FN1) 
[19], an important gene, playing critical role in tumor invasiveness and metastasis 
of GC [20, 21].
The role of RUNX2 has been also described in colon cancer. It has been found 
that RUNX2 promoted cell proliferation and invasion of colon cancer cells via estro-
gen/ERbeta pathway [10]. More recently, it has been demonstrated that RUNX2 
could interact with BRG1 to target CD44 for promoting invasion and migration 
of colorectal cancer cells [22]. It has been also recently reported that Integrative 
multi-omics analysis of a colon cancer cells with heterogeneous Wnt activity reveals 
RUNX2 as an epigenetic regulator of Epithelial–mesenchymal transition (EMT), 
the critical process which promotes cancer metastasis, stemness and resistance to 
treatment [23].
The contribution of RUNX2 to the promotion of other cancer types, including 
thyroid cancer, osteosarcoma and melanoma has been also reported. RUNX2 acti-
vates expression of MMP2, MMP13, MMP14, and OPN, promoting the invasive and 
migratory activity of thyroid cancer cells [6, 24]. Osteosarcoma cells with siRNA 
depletion of RUNX2 show a reduction in motility. The genomic promoter of RUNX2 
in osteosarcoma shows genes involved in cancer cell motility including FAK/PTK2 
and TNL1 [6, 25]. The role of RUNx2 has been well studied in melanoma. Our group 
has extensively contributed to the understanding of the role of RUNX2 in this lead-
ing skin cancer.
3. Role of RUNX2 in melanoma promotion
Melanoma malignancy has a very high mortality rate and a resistance to chemo-
therapy [26]. Of these melanoma malignancies, a study reflected almost half of 
patients had bone metastases [27]. Melanocytes arise from the neural crest and 
show progressive stemness features. This renders melanoma to be such a highly 
metastatic cancer once the process has started [13]. Malignant melanoma has been 
described to have a higher expression level of RUNX2 than normal melanocytes 
[26]. As other cancer types, Runx2 has been investigated in connection to the 
progression, development, and metastasis of tumors as well as the epithelial 
to mesenchymal transition (EMT). It has been shown that the RUNT domain 
of RUNX2 affects EMT and promote bone metastasis in melanoma via several 
mechanisms, including WWTR1 and TGF-beta [26, 27].
The interaction of RUNX2 with the PI3K/AKT signaling pathway is critical 
for tumor invasion and metastasis [28]. AKT interacts with RUNX2 via different 
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mechanisms, including phosphorylating/activating of RUNX2 or RUNX2 modula-
tors. Reciprocally, the activation of the PI3K/AKT pathway by RUNX2 has been also 
reported. This mutual activation, maintain a constitutive AKT activation and high 
expression of RUNX2 in cancer cells, and constitute one of a major driving force for 
tumor progression and metastasis in melanoma (Figure 3).
4.  Role of RUNX2 in melanoma progression and acquired resistance to 
BRAFi
RUNX2 was initially described as one of the transcription factors whose expres-
sion was significantly correlated with elevated levels of the non-canonical signaling 
member of the WNT family, WNT5A, following chronic treatment (over 10 weeks) 
with the BRAF inhibitors PLX4720 and PLX4032 [29]. We previously showed that 
RUNX2-deficient melanoma cells, displayed a significant down-regulation of 
leading receptor tyrosine kinases, EGFR, IGF-1R, PDGFRβ and AXL. Our finding 
strongly suggested a critical role for RUNX2 in mediating intrinsic RTK-associated 
pro-oncogenic properties in melanoma. In addition, we demonstrated a significant 
up-regulation of RUNX2 expression and concomitant up-regulation of EGFR, 
IGF-1R and AXL in melanoma cells rendered resistant to PLX4720 [30]. We then 
reported that PLX4720-resistant cells developed in an in vivo context exhibit an 
increase in RUNX2 levels when re-exposed to PLX4720 in vitro. These findings 
strongly suggest that RUNX2 could play a critical role in acquired resistance to 
PLX4720. In order to address the relevance of these findings in human melanoma, 
clinical data from a cohort containing samples from untreated tumors and tumors 
treated with vemurafenib and dabrafenib respectively [31] were analyzed. Probes 
for all three main RUNX2 transcripts were represented on the array. We found that 
the expression of RUNX2 isoform 3 is significantly higher in vemurafenib-treated 
patients compared to the untreated group (p = 0.0024). These results showing the 
up-regulation of RUNX2 in melanoma lesions from patients treated with vemu-
rafenib, strongly suggest that chronic exposure to BRAFi (PLX4720/vemurafenib) 
could favor RUNX2 up-regulation, leading to RTK up-regulation and the induction 
of acquired drug resistance to BRAFi [30].
The mechanism(s) leading to RUNX2 up-regulation in BRAFi-resistant 
melanoma cells have yet to be discovered. One possible mechanism would involve 
Figure 3. 
Role RUNX2/PIT3K/AKT axis in cancer invasion and metastasis. PIT3/AKT promotes cancer invasion 
and metastasis via RUNX2. Activation loop between RUNX2 and PIT3/AKT enables the amplification of 
oncogenic signaling via many factors. Activation of RUNX2 lead to the promotion of cancer invasion and 
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WNT5A and the WNT5A-mediated activation of the PI3K/AKT pathway [29]. 
As RUNX2 expression is increased by the PI3K/AKT pathway signaling [28, 30], 
elevated WNT5A expression and subsequent AKT pathway activation could result 
in RUNX2 overexpression. Therefore, any kinase rewiring that leads to hyper-
activated PI3K/AKT signaling in melanomas resistant to BRAFi [32] would provide 
a favorable context for high RUNX2 expression.
5. Conclusion
Besides, its indispensable role in bone development, the transcription factor 
RUNX2 is a critical player in the promotion of several cancers. Important oncogenic 
pathways, including PI3K/AKT axis are involved in mediating the effects of RUNX2. 
We believe that targeting RUNX2 or its modulators may open novel therapeutic 
avenues for cancer.
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